Biperiden and Haloperidol Plasma Levels and Extrapyramidal Side Effects in Schizophrenic Patients

1997 ◽  
Vol 36 (2) ◽  
pp. 69-72 ◽  
Author(s):  
Kurt Meszaros ◽  
Elisabeth Lenzinger ◽  
Kurt Hornik ◽  
Georg Schönbeck ◽  
Reinhold Hatzinger ◽  
...  
Keyword(s):  
Side Effects ◽  
Plasma Levels ◽  
Extrapyramidal Side Effects ◽  
Schizophrenic Patients

Neuroleptic Prescription for Chinese Schizophrenics in Hong Kong

1992 ◽  
Vol 26 (2) ◽  
pp. 262-264 ◽  
Author(s):  
Helen Chiu ◽  
Sing Lee ◽  
C.M. Leung ◽  
Y.K. Wing
Keyword(s):  
Hong Kong ◽  
Side Effects ◽  
High Frequency ◽  
Anticholinergic Drugs ◽  
Extrapyramidal Side Effects ◽  
High Potency ◽  
Frequency Of Use ◽  
Daily Dose ◽  
Schizophrenic Patients ◽  
The Mean

There are very few studies on the pattern of neuroleptic prescription for schizophrenics in Asia. 106 schizophrenic patients in a psychiatric unit of a general teaching hospital in Hong Kong were surveyed. The mean daily dose (in chlorpromazine equivalent) was low (568.5mg). The mean daily dose of high potency agents was four times that of low potency agents. A high frequency of use of anticholinergic drugs may indicate that Chinese are more susceptible to acute extrapyramidal side-effects.

Sulpiride: an advance in neuroleptics?

1984 ◽  
Vol 22 (8) ◽  
pp. 31-32
Keyword(s):  
Side Effects ◽  
Social Withdrawal ◽  
Extrapyramidal Side Effects ◽  
Schizophrenic Patients ◽  
Substituted Benzamide ◽  
The Uk

Sulpiride (Dolmatil - Squibb) is a substituted benzamide related to metoclopramide. It has only recently been marketed in the UK, but has been used in Europe for many years. The manufacturer claims that the drug has both antidepressive and neuroleptic properties, and that it is of particular benefit for schizophrenic patients who develop social withdrawal. Extrapyramidal side effects are claimed to be less than with conventional neuroleptics.

Quetiapine in relapsing schizophrenia: clinical efficacy and effect on monoaminergic parameters

2003 ◽  
Vol 15 (3) ◽  
pp. 133-139 ◽  
Author(s):  
F. M. M. A. van der Heijden ◽  
W. M. A. Verhoeven ◽  
D. Fekkes ◽  
A. E. S. Sijben ◽  
S. Tuinier
Keyword(s):  
Side Effects ◽  
Treatment Effect ◽  
Biochemical Parameters ◽  
Controlled Trial ◽  
Response To Treatment ◽  
Extrapyramidal Side Effects ◽  
Open Label ◽  
Schizophrenic Patients ◽  
Efficacy Measures ◽  
Efficacy Parameters

Methods:Tolerability, safety and effectiveness of quetiapine in an in-patient group with a relapse of schizophrenia and the possible role of plasma amino acid concentrations, 5-HT parameters and HVA in the prediction of response to treatment were investigated in an open-label baseline-controlled trial of 14 weeks in 21 hospitalized schizophrenic patients. Responders were defined as those patients who exhibit at least a 40% reduction of BPRS total scores. Secondary efficacy measures were the PANSS, the Clinical Global Impression (CGI)-severity scale and the MADRS. Extrapyramidal side-effects were evaluated with the AIMS. Other side-effects were monitored at regular intervals. Amino acids and the derived tryptophan and tyrosine ratios, as well as monoaminergic parameters, were assessed in plasma at baseline and at weeks 3, 6 and 14.Results:Treatment with quetiapine resulted in the predefined treatment effect in 10 out of the 17 patients who completed at least 4 weeks of treatment. Effect in responders was observed on all efficacy parameters, including lower MADRS scores. No extrapyramidal side-effects emerged. Clinical and biochemical parameters did not predict response to treatment.Conclusions:This study demonstrates the moderate antipsychotic efficacy of quetiapine on preferentially positive symptoms in a group of relatively young schizophrenics. Some observed changes in biochemical parameters are discussed.

Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects

1981 ◽  
Vol 74 (4) ◽  
pp. 306-309 ◽  
Author(s):  
Lars Bolvig Hansen ◽  
Niels-Erik Larsen ◽  
Per Vesterg�rd
Keyword(s):  
Side Effects ◽  
Plasma Levels ◽  
Extrapyramidal Side Effects
Sign in / Sign up

Export Citation Format

Share Document